IBDEI2FN ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41263,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,41264,0)
 ;;=C82.39^^159^2004^70
 ;;^UTILITY(U,$J,358.3,41264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41264,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,41264,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,41264,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,41265,0)
 ;;=C82.30^^159^2004^71
 ;;^UTILITY(U,$J,358.3,41265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41265,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,41265,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,41265,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,41266,0)
 ;;=C82.49^^159^2004^72
 ;;^UTILITY(U,$J,358.3,41266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41266,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,41266,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,41266,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,41267,0)
 ;;=C82.40^^159^2004^73
 ;;^UTILITY(U,$J,358.3,41267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41267,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,41267,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,41267,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,41268,0)
 ;;=C82.99^^159^2004^74
 ;;^UTILITY(U,$J,358.3,41268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41268,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,41268,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,41268,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,41269,0)
 ;;=C82.90^^159^2004^75
 ;;^UTILITY(U,$J,358.3,41269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41269,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,41269,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,41269,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,41270,0)
 ;;=R59.1^^159^2004^60
 ;;^UTILITY(U,$J,358.3,41270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41270,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,41270,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,41270,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,41271,0)
 ;;=C91.40^^159^2004^79
 ;;^UTILITY(U,$J,358.3,41271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41271,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,41271,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,41271,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,41272,0)
 ;;=C91.42^^159^2004^77
 ;;^UTILITY(U,$J,358.3,41272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41272,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,41272,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,41272,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,41273,0)
 ;;=C91.41^^159^2004^78
 ;;^UTILITY(U,$J,358.3,41273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41273,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,41273,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,41273,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,41274,0)
 ;;=D57.01^^159^2004^80
 ;;^UTILITY(U,$J,358.3,41274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41274,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,41274,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,41274,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,41275,0)
 ;;=D57.00^^159^2004^81
 ;;^UTILITY(U,$J,358.3,41275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41275,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,41275,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,41275,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,41276,0)
 ;;=D57.02^^159^2004^82
 ;;^UTILITY(U,$J,358.3,41276,1,0)
 ;;=^358.31IA^4^2
